EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Botanical Sources: 10

Dong quai Angelica sinensis (Oliv.) Diels

Also called: dang gui, tang kuei, Chinese angelica

Dong quai (dang gui) is a perennial herb native to northern and central China. Its root has a long history in traditional Chinese medicine and is used as a "women's herb" for symptoms associated with menstruation and menopause.

Category
Botanical
Part used
Root (the European Pharmacopoeia describes smoke-dried root)
Strongest evidence
C Limited
Native range
Native to northern and central China (POWO: "N. & Central China")
Reviewed
2026-10-29

Class 3 Limited studies in people. No review stating a count was found; EMA (2013) calls Hirata 1997 the only controlled trial of its estrogenic effect. This entry cites 2 RCTs of dong quai alone: Hirata 1997 (71 women) and Fung 2017 (healthy volunteers, platelet function). [4]

Fact-checked 2026-10-29 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

3 topics studied1 body area · strongest grade C

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Dong quai does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Dong quai, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Hot flashes and other menopausal symptoms (dong quai alone)CA single 24-week double-blind trial in 71 postmenopausal women found no difference from placebo in hot flashes, Kupperman index, endometrial thickness or vaginal cell maturation. [4]
Menopausal symptoms (all studies, including formulas)CMSK describes findings on dong quai for menopausal symptoms as inconclusive and notes it was ineffective against hot flashes in men. [1]
Amenorrhea caused by antipsychotic drugsCMSK cites a systematic review that found dong quai useful for antipsychotic-induced amenorrhea; trial sizes and quality are not described in MSK's summary. [1]

Main constituents: Alkyl phthalides such as (Z)-ligustilide (main essential-oil components) and ferulic acid [2]; Coumarins, including phototoxic furocoumarins (bergapten, psoralen, imperatorin), plus safrole and isosafrole in the essential oil, with no quantitative data [2]

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    Health Canada: do not use if pregnant; ask a practitioner before use if breastfeeding.

    3 statements in the profile.

    Details and sources
  • Interactions with medicines
    5 listed

    Warfarin and antiplatelet drugs; Warfarin; Clozapine; CYP3A4 substrates; Birth control pills, hormone therapy, blood thinners

    Details and sources
  • Cancer evaluations (IARC, NTP)
    1 found

    Each names the exact material tested, which may differ from a supplement.

    Details and sources
  • FDA new dietary ingredient notifications
    3 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    Stated

    Health Canada NNHPD Dong Quai monograph (May 29, 2026), adults 18 and older: 4.5-15 grams of dried root per day …

    Details and sources
  • EMA found preliminary evidence of toxicological concerns: the root contains phototoxic furocoumarins, and its essential oil contains safrole (described as a genotoxic carcinogen) and isosafrole (a weak liver carcinogen in rats and mice); no quantitative data on their content exist. [2]
  • Health Canada label requirements: do not use if pregnant or if you have diarrhea, hemorrhagic diseases or heavy periods; avoid sun exposure; ask a practitioner if taking blood thinners, birth control pills or hormone therapy. [5]
  • Reported adverse reactions include bloating, appetite loss, diarrhea, photosensitivity, gynecomastia and hypertension. [1]
  • Dong quai showed estrogenic activity in vitro and promoted growth of estrogen receptor-positive breast tumors in mice; MSK advises people with hormone-sensitive cancers to consult their physicians. [1]
  • LactMed: dong quai is best avoided during breastfeeding. [6]
Interactions

Interactions

Dong quai
From the table below 5 interactions the sources name. Tap one to read what happens. A line means a documented or possible interaction, not its size.
Known interactions of Dong quai
WithWhat happens
Warfarin and antiplatelet drugsMay increase the risk of bleeding in patients taking warfarin and antiplatelet drugs. [6]
WarfarinBleeding when warfarin is combined with dong quai is listed among plausible herb-drug interactions; many such reports lack laboratory analysis of the preparations. [7]
AnticoagulantsMSK: may have additive anticoagulant effect, though this appears limited in a human study; elevated PT/INR is listed as a lab interaction. [1]
ClozapineDong quai was a moderate-to-strong inducer of clozapine metabolism in two case reports. [1]
CYP3A4 substratesProlonged use can induce CYP3A4 via the pregnane X receptor and may lower levels of substrate drugs; clinical relevance not known. [1]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Quality

Identity, quality and standardization

  • European Pharmacopoeia: smoke-dried, whole or fragmented root collected in late autumn, containing at least 0.050% trans-ferulic acid. [2]
Regulation

Regulatory status

  • US: FDA states that, by law, it does not approve dietary supplements before they are marketed; firms are responsible for the safety and labeling of their products. [9]
  • EU: in 2013 the HMPC concluded that an EU herbal monograph cannot be established, citing insufficient evidence of traditional use and preliminary toxicological concerns. [3]
  • Canada: Health Canada's Dong Quai monograph (May 29, 2026) covers oral products of the dried root for adults, with traditional Chinese medicine uses. [5]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • (Z)-ligustilide and other alkyl phthalides Phthalides [P3]
  • (E)-ferulic acid Phenylpropanoids [P3]
  • Furocoumarins (bergapten, psoralen, imperatorin, oxypeucedanin) Coumarins (furocoumarins) [P3]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 3 entries naming Angelica sinensis or Radix Angelicae Sinensis, all multi-ingredient combinations (earliest NDI 368 submitted 2005-12-07; most recent NDI 954 submitted 2016-10-28). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P1]
  • A fourth entry, NDI 372 (submitted 2006-01-13), lists several products including one named "Ejiao Danggui Heji" (danggui is another name for dong quai). [P1]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC classification of dong quai (Angelica sinensis root) was found in the IARC Monographs list of classifications (Volumes 1–142, list updated 2026-07-23; checked 2026-10-29). [P2]
  • No NTP technical report (2-year study) on dong quai (Angelica sinensis root) was found in NTP's list of technical reports (checked 2026-10-29). [P9]
  • EMA (2013) notes the root's essential oil contains safrole and isosafrole and that the root contains furocoumarins, with no quantitative data; these are constituents, not evaluations of the root itself. [P3]
  • IARC evaluations of individual constituents (pure compounds, not the root): safrole Group 2B and isosafrole Group 3 (Vol 10, Suppl 7, 1987); 5-methoxypsoralen (bergapten) Group 2A (Vol 40, Suppl 7, 1987). [P10]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • Warfarin and antiplatelet drugs: LactMed: may increase the risk of bleeding. [P5]
  • Warfarin: Listed among plausible herb-drug interactions causing bleeding (Lancet review, 2000). [P6]
  • Clozapine: Moderate-to-strong inducer of clozapine metabolism in two case reports. [P4]
  • CYP3A4 substrates: Prolonged use can induce CYP3A4 via the pregnane X receptor; clinical relevance not known. [P4]
  • Birth control pills, hormone therapy, blood thinners: Health Canada label: ask a health care practitioner before use if taking these medications. [P7]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity test or examination of each component that is a dietary ingredient — Required by 21 CFR 111.75(a)(1)(i) unless FDA grants an exemption petition under 111.75(a)(1)(ii) [P8]
  • trans-Ferulic acid assay (European Pharmacopoeia minimum 0.050%) — Compendial marker for Angelica sinensis root [P3]
  • Furocoumarin and safrole/isosafrole content — EMA: the root contains phototoxic furocoumarins and the essential oil contains safrole and isosafrole, with no quantitative data on their content in the root or preparations [P3]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • No published information found in the sources checked.

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • Health Canada NNHPD Dong Quai monograph (May 29, 2026), adults 18 and older: 4.5-15 grams of dried root per day; consult a practitioner for use beyond 6 months. [P7]

Pregnancy and breastfeeding

  • Health Canada: do not use if pregnant; ask a practitioner before use if breastfeeding. [P7]
  • MSK: pregnant and breastfeeding women should avoid dong quai. [P4]
  • LactMed: best avoided during breastfeeding. [P5]

Sources for this profile

  1. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  2. IARC Monographs. List of Classifications (checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
  3. EMA, HMPC. Assessment report on Angelica sinensis (Oliv.) Diels, radix. EMA/HMPC/614586/2012 (9 July 2013), 2013-07-09. ema.europa.eu
  4. Memorial Sloan Kettering Cancer Center. About Herbs: Dong Quai (last updated July 29, 2026), 2026-07-29. mskcc.org
  5. Drugs and Lactation Database (LactMed). Dong Quai (record dated June 15, 2026) (PMID 30000896), 2026-06-15. pubmed.ncbi.nlm.nih.gov
  6. Fugh-Berman A. Herb-drug interactions. Lancet 2000;355(9198):134-8 (PMID 10675182), 2000-01-08. pubmed.ncbi.nlm.nih.gov
  7. Health Canada, NNHPD. Dong Quai - Angelica sinensis monograph (date May 29, 2026), 2026-05-29. webprod.hc-sc.gc.ca
  8. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
  9. National Toxicology Program. Technical Reports (list of TR studies; checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
  10. IARC Monographs. Agents classified by the IARC Monographs, Volumes 1–142 (list updated 2026-07-23; checked 2026-10-29), 2026-07-23. monographs.iarc.who.int
Sources

Sources

  1. Memorial Sloan Kettering Cancer Center. About Herbs: Dong Quai (last updated July 29, 2026), 2026-07-29. mskcc.org
  2. EMA, HMPC. Assessment report on Angelica sinensis (Oliv.) Diels, radix. EMA/HMPC/614586/2012 (9 July 2013), 2013-07-09. ema.europa.eu
  3. EMA, HMPC. Public statement on Angelica sinensis (Oliv.) Diels, radix. EMA/HMPC/681574/2012 (9 July 2013), 2013-07-09. ema.europa.eu
  4. Hirata JD, et al. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril 1997;68(6):981-6 (PMID 9418683), 1997-12. pubmed.ncbi.nlm.nih.gov
  5. Health Canada, NNHPD. Dong Quai - Angelica sinensis monograph (date May 29, 2026), 2026-05-29. webprod.hc-sc.gc.ca
  6. Drugs and Lactation Database (LactMed). Dong Quai (record dated June 15, 2026) (PMID 30000896), 2026-06-15. pubmed.ncbi.nlm.nih.gov
  7. Fugh-Berman A. Herb-drug interactions. Lancet 2000;355(9198):134-8 (PMID 10675182), 2000-01-08. pubmed.ncbi.nlm.nih.gov
  8. Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Angelica sinensis (Oliv.) Diels (accessed 2026-10-29; native range: "N. & Central China"), 2026-10-29. powo.science.kew.org
  9. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
  10. Fung FY, et al. A randomized, double-blind, placebo-controlled study on the anti-haemostatic effects of Curcuma longa, Angelica sinensis and Panax ginseng. Phytomedicine 2017;32:88-96 (PMID 28732813), 2017-04-10. pubmed.ncbi.nlm.nih.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.